Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2024; 16(1): 1-7
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.1
Present situation and prospect of immunotherapy for unresectable locally advanced esophageal cancer during peri-radiotherapy
Feng-Mei Wang, Peng Mo, Xue Yan, Xin-Yue Lin, Zhi-Chao Fu
Feng-Mei Wang, Department of Obstetrics and Gynecology, Fuzong Clinical Medical College (900th Hospital), Fujian Medical University, Fuzhou 350025, Fujian Province, China
Feng-Mei Wang, Department of Obstetrics and Gynecology, Dongfang Hospital, Xiamen University, Fuzhou 350025, Fujian Province, China
Peng Mo, Xue Yan, Xin-Yue Lin, Zhi-Chao Fu, Department of Radiotherapy, Fuzong Clinical Medical College (900th Hospital), Fujian Medical University, Fuzhou 350025, Fujian Province, China
Zhi-Chao Fu, Department of Radiotherapy, Dongfang Hospital, Xiamen University, Fuzhou 350025, Fujian Province, China
Author contributions: Wang FM, Mo P, Yan X contributed equally to this work; Fu ZC designed the research study; Wang FM, Mo P, Yan X, Lin XY, Fu ZC performed the research; Wang FM, Mo P, Yan X, Lin XY analyzed the data and wrote the manuscript; all authors have read and approve the final manuscript.
Supported by Natural Science Foundation of Fujian Province, No. 2021J011259.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Chao Fu, MD, PhD, Doctor, Department of Radiotherapy, Fuzong Clinical Medical College (900th Hospital), Fujian Medical University, No. 156 West Second Ring Road North, Fuzhou 350025, Fujian Province, China. fauster1112@126.com
Received: October 21, 2023
Peer-review started: October 21, 2023
First decision: November 7, 2023
Revised: November 14, 2023
Accepted: December 6, 2023
Article in press: December 6, 2023
Published online: January 15, 2024
Processing time: 82 Days and 4.7 Hours
Core Tip

Core Tip: For unresectable or inoperable non-metastatic esophageal cancer, concurrent radiotherapy and chemotherapy is the standard treatment recommended by various guidelines. Because its curative effect is still not ideal, it is still necessary to explore radical radiotherapy and chemotherapy in the future, and it is considered to be very promising to combine with immune drugs represented by anti-programmed death protein-1. This paper mainly discusses how to combine radical concurrent radiotherapy and chemotherapy with immunotherapy for unresectable local late esophageal cancer.